Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

15.0%

3 terminated/withdrawn out of 20 trials

Success Rate

84.2%

-2.3% vs industry average

Late-Stage Pipeline

35%

7 trials in Phase 3/4

Results Transparency

88%

14 of 16 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 2
8(40.0%)
Phase 3
6(30.0%)
Phase 1
4(20.0%)
Phase 4
1(5.0%)
N/A
1(5.0%)
20Total
Phase 2(8)
Phase 3(6)
Phase 1(4)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT01016834Phase 4Completed

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Role: collaborator

NCT05534620Phase 1Completed

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Role: collaborator

NCT02882191Phase 2Completed

Evaluation of the Efficacy and Safety of LevoCept

Role: collaborator

NCT03785366Phase 3Completed

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

Role: collaborator

NCT03927703Phase 3Completed

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

Role: collaborator

NCT04535531Phase 3Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

Role: collaborator

NCT03927716Phase 3Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Role: collaborator

NCT04465916Phase 2Terminated

Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Role: collaborator

NCT03283462Not ApplicableCompleted

Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)

Role: collaborator

NCT04013334Phase 2Unknown

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Role: collaborator

NCT03847389Phase 1Terminated

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

Role: collaborator

NCT01746095Phase 2Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Role: collaborator

NCT01817582Phase 2Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Role: collaborator

NCT00823862Phase 1Completed

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Role: collaborator

NCT00600067Phase 2Completed

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

Role: collaborator

NCT00486291Phase 2Completed

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Role: collaborator

NCT00737633Phase 2Terminated

Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults

Role: collaborator

NCT00432562Phase 1Completed

A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

Role: collaborator

NCT00752050Phase 3Completed

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

Role: collaborator

NCT00752258Phase 3Completed

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

Role: collaborator

All 20 trials loaded